Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
FimmCyte logo — First disease modifying treatment for Endometriosis.

FimmCyte

First disease modifying treatment for Endometriosis.

Founded 2022 Switzerland Basel, Switzerland 7 employees Seed Total: $1.30M Biotechnology, Health Care

General Information

Company Name FimmCyte
Founded Year 2022
Location Switzerland Basel, Switzerland +1
Employees 7
Industries Biotechnology, Health Care
Funding Stage Seed
Social

Get notified when FimmCyte moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About FimmCyte

FimmCyte, founded in 2022 and headquartered in Switzerland, is a pioneering company in the Biotechnology and Health Care sectors. The company is noteworthy for its groundbreaking approach to addressing endometriosis, a debilitating condition affecting millions globally, with what they claim to be the “First disease modifying treatment for Endometriosis.”

Recently, FimmCyte secured a Fr.1.00M Convertible Note investment on 01 February 2024 from the UZH Life Sciences Fund. This infusion of capital will likely bolster their R&D capabilities and expedite the regulatory pathway. The involvement of the UZH Life Sciences Fund not only provides financial support but also serves as an endorsement of the company’s potential to significantly impact the treatment landscape of endometriosis. Investors should monitor FimmCyte for its capacity to innovate within a healthcare segment ready for disruption and socially impactful solutions.

Taxonomy: Endometriosis treatment, Disease modifying therapies, Fibro-inflammatory diseases, Healthcare innovation, Pharmaceutical development, Women's health, Medical research, Drug development, Chronic disease management, Therapeutic solutions, Biomedical advancements

Services & Products

Development of targeted immunotherapy solutions
Research on disease-modifying treatments for fibro-inflammatory diseases
Innovative therapies for endometriosis

Target Customers

Patients with endometriosis Individuals suffering from chronic fibro-inflammatory conditions Healthcare providers seeking advanced treatment options

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note •••••• 1 •••• •••• 01 Feb 2024
Unknown •••••• - 01 Sep 2023
Grant •••••• 1
Investor
01 Jul 2022
Spinout •••••• 1 •••• •••• 01 Feb 2022

Latest News

View All
10 most innovative Swiss startups to watch in 2024 and beyond! — Eu-startups
10 most innovative Swiss startups to watch in 2024 and beyond!
Eu-startups Mar 15, 2024

FimmCyte Alternatives & Competitors

View All Alternatives
FimmCyte vs
T3D Therapeutics, Inc.
T3D Therapeutics, Inc. United States

Developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other neurodegene...

Series Unknown
12 employees
Biotechnology
FimmCyte vs
CIBUS BIOTECHNOLOGIES
CIBUS BIOTECHNOLOGIES

Pioneering the future of animal health with portable and remote diagnostics for swift disease detect...

Biotechnology, Health Care
FimmCyte vs
Proteon Therapeutics
Proteon Therapeutics

Pioneering medical advancements to improve renal and vascular health through innovative tissue remod...

Post Ipo Equity
Biotechnology, Pharmaceutical
View all alternatives

FAQ About FimmCyte

First disease modifying treatment for Endometriosis.
FimmCyte was founded in 2022.
FimmCyte is headquartered in Basel, Switzerland.
FimmCyte operates in the following industries: Biotechnology, Health Care.
FimmCyte has approximately 7 employees.
FimmCyte has completed 4 funding rounds, raising a total of $1.30M. The latest funding stage is Seed.
FimmCyte offers: Development of targeted immunotherapy solutions, Research on disease-modifying treatments for fibro-inflammatory diseases, Innovative therapies for endometriosis.
Top alternatives and competitors to FimmCyte include T3D Therapeutics, Inc., CIBUS BIOTECHNOLOGIES, Proteon Therapeutics, G3P, Dunad Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FimmCyte and T3D Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors FimmCyte and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy